Clinical Trials
1,165 trialsNCT05181462 2026-05-27
TRIFOUR
Cantargia AB
Phase 1/2 Completed
NCT06266143 2026-05-27
A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer
Wuhan YZY Biopharma Co., Ltd.
Phase 1/2 Completed
NCT04053205 2026-05-22
A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1/2 Completed
NCT05301764 2026-05-20
A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue Sarcoma
Lyvgen Biopharma Holdings Limited
Phase 1/2 Completed
NCT05900986 2026-05-20
LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer
Integro Theranostics
Phase 1/2 Completed
NCT04742101 2026-05-18
Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia
Servier
Phase 1/2 Completed
NCT03910660 2026-05-15
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
BioXcel Therapeutics Inc
Phase 1/2 Completed
NCT04843709 2026-05-15
A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors
Lepu Biopharma Co., Ltd.
Phase 1/2 Completed
NCT05173142 2026-05-15
A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors
Hutchmed
Phase 1/2 Completed
NCT05779163 2026-05-14
A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Completed
NCT02362035 2026-05-13
KEYNOTE145
Acerta Pharma BV
Phase 1/2 Completed
NCT04322006 2026-05-13
A Phase I/II Study of TJ004309 for Advanced Solid Tumor
TJ Biopharma Co., Ltd.
Phase 1/2 Completed
NCT03758287 2026-05-12
Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative
Sunshine Lake Pharma Co., Ltd.
Phase 1/2 Completed
NCT04902872 2026-05-12
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
Phase 1/2 Completed
NCT01171898 2026-05-11
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
Aragon Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT04145349 2026-05-11
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor
Eli Lilly and Company
Phase 1/2 Completed
NCT04505826 2026-05-11
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
Olema Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT06668987 2026-05-11
A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Recurrent Meningioma
Heron Neutron Medical Corp.
Phase 1/2 Completed
NCT05532722 2026-05-06
ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
Abcuro, Inc.
Phase 1/2 Completed
NCT04083534 2026-05-04
First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)
Regeneron Pharmaceuticals
Phase 1/2 Completed
NCT01625234 2026-04-30
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
Xcovery Holdings, Inc.
Phase 1/2 Completed
NCT03872778 2026-04-30
NeoRay
Advanced Accelerator Applications
Phase 1/2 Completed
NCT02661542 2026-04-23
Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas
Fujifilm Pharmaceuticals U.S.A., Inc.
Phase 1/2 Completed
NCT05975073 2026-04-22
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
Amgen
Phase 1/2 Completed
NCT06614140 2026-04-22
Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors
Seqker Biosciences, Inc.
Phase 1/2 Completed
NCT01802632 2026-04-20
AURA
AstraZeneca
Phase 1/2 Completed
NCT05189093 2026-04-20
Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma
Hangzhou Hanx Biopharmaceuticals, Ltd.
Phase 1/2 Completed
NCT04174716 2026-04-17
VASTUS
Idience Co., Ltd.
Phase 1/2 Completed
NCT04072952 2026-04-15
mBC
Arvinas Inc.
Phase 1/2 Completed
NCT05304936 2026-04-15
HCW9218 for Advanced Pancreatic Cancer
ImmunityBio, Inc.
Phase 1/2 Completed
NCT02625480 2026-04-09
ZUMA-4
Gilead Sciences
Phase 1/2 Completed
NCT04420884 2026-04-08
iintune-1
Takeda
Phase 1/2 Completed
NCT01968109 2026-04-06
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03459222 2026-04-06
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
Phase 1/2 Completed
NCT06238687 2026-04-06
A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors
Tasly Pharmaceutical Group Co., Ltd
Phase 1/2 Completed
NCT02077881 2026-04-03
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Phase 1/2 Completed
NCT04673617 2026-04-03
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Artiva Biotherapeutics, Inc.
Phase 1/2 Completed
NCT06492304 2026-04-03
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
CRISPR Therapeutics
Phase 1/2 Completed
NCT03744468 2026-04-02
Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors
BeOne Medicines
Phase 1/2 Completed
NCT05516914 2026-04-01
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Completed
NCT05586516 2026-03-30
A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer
iOnctura
Phase 1/2 Completed
NCT03328026 2026-03-27
Combination Study of SV-BR-1-GM With Retifanlimab
BriaCell Therapeutics Corporation
Phase 1/2 Completed
NCT05039177 2026-03-25
HERKULES-3
Erasca, Inc.
Phase 1/2 Completed
NCT04990323 2026-03-24
US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies
ExCellThera inc.
Phase 1/2 Completed
NCT05963997 2026-03-23
SUMIT-ELA
Carrick Therapeutics Limited
Phase 1/2 Completed
NCT04417088 2026-03-20
Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy
InSightec
Phase 1/2 Completed
NCT04143711 2026-03-18
Study of DF1001 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
Phase 1/2 Completed
NCT05198804 2026-03-18
A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1/2 Completed
NCT01615029 2026-03-16
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 1/2 Completed
NCT04332653 2026-03-09
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
Phase 1/2 Completed